• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review)

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA111)

Status:	History
Expected date of issue:	March 2011
Referral date:	January 2010
Wave:	R111
Process:	MTA
Topic area: Central nervous system Mental health and behavioural conditions

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Andrew Dillon
Technical Lead:	Jennifer Priaulx
Communications manager:	Alice Law
Project manager:	Kate Moore
Assessment group:	Peninsula Technology Assessment Group (PenTAG)

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	5 March 2010
1st appraisal committee meeting:	25 August 2010
2nd appraisal committee meeting:	25 November 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Eisai/Pfizer (donepezil) Lundbeck (memantine) Novartis Pharmaceuticals (rivastigmine) Shire Pharmaceuticals (galantamine) Patient/carer groups Alzheimer’s Society The Neurological Alliance Professional groups Association of British Neurologists British Geriatrics Society Royal College of Nursing Royal College of Physicians Royal College of Psychiatrists Others Department of Health NHS Islington NHS West Kent Welsh Assembly Government General Commissioning Support Appraisals Service Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator manufacturers Eisai/Pfizer (donepezil) Lundbeck (memantine) Novartis Pharmaceuticals (rivastigmine) Shire Pharmaceuticals (galantamine) Relevant research groups Institute for Ageing and Health Research Institute for the Care of Older People Assessment groups Peninsula Technology Assessment Group, University of Exeter National Institute for Health Research Health Technology Assessment Programme Associated guideline groups National Collaborating Centre for Mental Health Associated public health groups None

Top

 

Project history

Date Update September 2009       A draft scope for consultation was issued. 13 November 2009            Invitations to participate were sent along with the final scope. The scope was issued in September for the treatment of mild to moderate Alzheimer’s disease, and included a note for consultation that  NICE would be consulting on a review proposal for appraising the clinical and cost effectiveness of memantine for severe Alzheimer’s disease. Following the consultation exercise, and in line with Technology Appraisal Guidance 111, the scope for this appraisal was broadened to include treatment of severe Alzheimer's disease. An opportunity was given to comment on the aspects of the scope which relate solely to the inclusion of people with severe Alzheimer’s disease. 5 January 2010       A consultee information meeting was held. 18 January 2010 Following receipt of comments on the broadening of the scope to include severe Alzheimer’s disease, no amendments have been made. This confirms that the scope issued in November 2009 is final. A table of responses to comments received was sent to Consultees and Commentators and posted on the website.

Top

 

Key documents

Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): EIA form for guidance development 29 March 2011 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): final appraisal determination 18 January 2011 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation 07 October 2010 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): assessment report 14 July 2010 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final protocol 20 January 2010 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final matrix 07 December 2009 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): final scope 20 November 2009 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the provisional matrix 20 November 2009 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): response to comments on the draft scope 20 November 2009 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): provisional matrix 24 September 2009 Alzheimer's disease (mild to moderate) - donepezil, galantamine, rivastigmine and memantine (part review): draft scope 24 September 2009

This page was last updated: 29 March 2011